Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Interview: Putting The Pieces Together For Combo Products Oversight

Bradley Thompson has been shepherding the Combination Products Coalition for more than a decade. He says the recent spotlight from FDA and other policymakers put on the combo-products space, including in a recent user-fee deal, is a welcome development after a period of neglect. Thompson spoke to Medtech Insight about the numerous reforms in the works and the state of the sector.

Policy and Regulation Medical Device Regulation

Turkey To Strengthen Local Medtech; Puts Up $1bn+ For Investing

The Turkish market for medical technologies is expected to see significant growth on the back of new hospital construction, and the government is looking to use its purchasing power to promote local production, but the country’s political environment may pose a challenge to investors.

Turkey Market Access Policy

EU Regs: Resource Gaps Could Threaten Existing Products, But Some Protections In Place

There is still a lack of clarity over whether notified bodies and competent authorities will find sufficient resources for the smooth implementation of the forthcoming Medical Devices and IVD Regulations. Does this mean some products considered safe today may have to be removed unnecessarily from the EU market?

Europe Medical Devices Policy and Regulation

MDIC Project Looks To New P-Value Possibilities

The Medical Device Innovation Consortium is launching a new pilot project with FDA and the Michael J. Fox Foundation to incorporate patient preference into device trials in a "scientifically valid way," according to MDIC CEO Bill Murray, who spoke to MedTech Insight from the AdvaMed 2016 conference in Minneapolis. In our video interview, Murray discusses the project's aim to adjust the statistical design of a study for Parkinson's disease based on patients' willingness to accept risks.

Policy and Regulation Clinical Development and Trials Clinical Trials

Recent Tweets from Medtech Insight

Policy & Regulation Explore this Topic

Set Alert for Policy & Regulation

French Medtechs Demand Attention To Ongoing Reimbursement Delays

French medtech manufacturers are expecting positive results from recent ministerial efforts to make the national health-care products reimbursement agency, the CEPS, speed up its current slow handling of applications for products and services to enter commercial use in France's public-health system.

France Market Access Reimbursement

Next Step In Global Convergence: FDA Looks To Make IMDRF Software Guidance Its Own

The US agency issued a draft guidance on clinical evaluation considerations for "software as a medical device." But FDA did not write the guidance internally. Instead it is an International Medical Device Regulators Forum document that was put together collaboratively by regulatory officials from across the globe. This is the first time FDA is attempting to wholesale adopt an IMDRF guidance document as its own.

Policy and Regulation Regulation Medical Device

Latest From Policy and Regulation

Interview: Medtech’s Unique Market-Access Routes Demand Tailored Response For EU-Wide HTA

The European Commission is looking at initiatives for employing health technology assessment at the EU level. But the medtech industry is concerned that its own specific market-access routes are being overlooked while the commission focuses too narrowly on solutions more suited to the pharma industry. MedTech Europe’s Yves Verboven explains the industry's case in an interview.

Commercial Market Access

FDA Formally Classifies Cardiac Surgery Device, Robotic Arm

Both an arm prosthesis and a device used in transcatheter valve replacement will be regulated via class II, FDA announced this week.

Policy and Regulation Pre Market Regulation

New Industry Survey Recruits Device Firms For Study On Complaints, Failure Management

The confidential device industry survey can aid firms as they look to gain new insights into how competitors handle product complaints and failures, according to organizers of the study.

Policy and Regulation Quality Control

Warning Letter Roundup & Recap – Oct. 19

No device-related warning letters were released by US FDA the week of Oct. 19.

Device Warning Letters Policy and Regulation

Electronic Labeling Submissions Proposed For Home-Use Devices

US FDA is proposing a rule that would require manufacturers to electronically submit labeling and package inserts for class II and III devices that are intended for use outside health-care facilities. The agency is also planning a public database of the labeling.

Regulation Medical Device

UK Diagnostic Fret Over Loss of Support In Evidence Centers Restructure

Changes are afoot for the four UK Diagnostic Evidence Co-operatives that help generate clinical and cost-effectiveness data for innovative IVDs. Companies worry it could mean diagnostic industry needs get lost among broad medtech targets. Also, a roundup of the British In Vitro Diagnostics Association's key priorities, including the EU IVD Regulation, procurement issues, antimicrobial resistance, and of course, Brexit, highlighted at the group's 2016 annual meeting.

United Kingdom In Vitro Diagnostics

Commercial Explore this Topic

Set Alert for Commercial

Earnings Winners And Losers: ABT, ISRG, JNJ, STJ

Among the first batch of companies to have released their latest quarterly earnings this week are medtech bellwethers Johnson & Johnson, Abbott, St. Jude Medical, Intuitive Surgical and Roche. Here are our picks of who we believe to be the winner, loser and one to watch from this batch.

Financial Reports Companies Commercial

Latest From Commercial

J&J Pledges To Stop Animal Use In Sales Training

The manufacturer was facing PETA protests in response to a leaked plan to allow pigs to die as part of sales-rep training later this month.

Marketing and Sales Medical Device

Interview: Medtech’s Unique Market-Access Routes Demand Tailored Response For EU-Wide HTA

The European Commission is looking at initiatives for employing health technology assessment at the EU level. But the medtech industry is concerned that its own specific market-access routes are being overlooked while the commission focuses too narrowly on solutions more suited to the pharma industry. MedTech Europe’s Yves Verboven explains the industry's case in an interview.

Commercial Market Access

China Precision Medicine Push Boosting Genomic Business Forays

As the traditional lines between therapeutics and diagnostics become increasingly blurred, genomic testing is growing apace in China, boosted by the country’s national push into precision medicine. Deals and alliances are coming thick and fast as companies jostle for a slice of the growing pie.

China In Vitro Diagnostics

Cybersecurity Allegations, Safety Alert Will Not Impact St. Jude Acquisition, Abbott Affirms

Abbott Labs' CEO Miles White expressed strong confidence in St. Jude and an unimpeded acquisition of the firm in the wake of continued cybersecurity allegations and a device-safety advisory.

Medical Device Commercial

Digital Health – The Next Gold Rush Of Opportunities, Says Kaiser Permanente Ventures

Digital health is no longer a buzzword but a reality, with venture capital investment in this space reaching an all-time high. This Q&A with Jordan Kramer of Kaiser Permanente Ventures provides insight into why digital health investment has rocketed, how Kaiser Permanente's approach to investing in this sector, and where the opportunities and challenges lie for digital health start-ups.

Financing StartUps and SMEs

No Surprise As Abbott Cuts Loose Angio-Seal, Femoseal To Terumo

Abbott and St. Jude Medical are to lighten their cardiovascular portfolios – and hopefully facilitate the completion of Abbott's pending $25bn acquisition of St. Jude – by selling three product lines to Terumo. Two of the three product lines to be divested come as little surprise, but one product was acquired by Abbott only earlier this year.

M and A Cardiology

Clinical R&D Explore this Topic

Set Alert for Clinical R&D

Mass Spectrometry Makes Inroads Into The Clinical Lab

The use of mass spectrometry in IVD applications looks to be gaining momentum. In this article, Alina Kim, Sunayana Karra and Akash Kundu of Boston Biomedical Consultants report on new developments and innovations showcased at the American Association for Clinical Chemistry Annual (AACC) & Clinical Lab Expo (CLE) annual meeting that took place this summer. Players at the convention exhibited a range of Class I medical devices, research use only liquid chromatography tandem mass spectrometry (LC-MS/MS), matrix-assisted laser desorption/ionization (MALDI-TOF), inductively coupled plasma mass spectrometry (ICP-MS), sample preparation automation platforms, and software solutions.

In Vitro Diagnostics Cancer Innovation

Latest From Research and Development

electroCore Stimulates More Promise With Migraine Therapy

New research published in the Journal of Headache and Pain has demonstrated the potential of electroCore's noninvasive vagal nerve stimulation therapy for reducing menstrual migraine attacks by more than a third.

Neurology Clinical Trials

Liquid Biopsy, Particle-Beam Radiotherapy Get 'Moonshot' Commitments

The White House announced 36 new project commitments under its ongoing Cancer Moonshot oncology initiative, including an ambitious project to create an open liquid-biopsy database and a NASA-NCI collaboration to explore the benefits of particle-beam radiotherapy.

Innovation Research and Development

Device Week – October 17, 2016

On this week's podcast, we discussed trends and challenges with adverse-event reporting in the US, lab-developed test marketing, some companion diagnostic data and a look ahead to this week's AdvaMed conference in Minneapolis.

Medical Device In Vitro Diagnostics

Myriad's Ovarian Cancer Test Proves Its Mettle as Tesaro Companion Dx

Myriad’s myChoice HRD test has demonstrated its ability to identify more than twice as many ovarian cancer patients who may benefit from treatment with Tesaro’s drug investigational drug niraparib, compared with patient stratification by germline-BRCA testing alone.

Clinical Trials Research and Development

Inivata Launches Major US Study To Back Liquid Biopsy Tech In Lung Cancer

Cambridge University spin-out Inivata has launched a major US clinical validation study to evaluate its liquid biopsy approach against tissue-based diagnostic methods in non-small cell lung cancer patients.

Cancer In Vitro Diagnostics

Mercator Moves To New Studies Following DANCE Success

Results of DANCE, the first large-scale trial of Mercator’s Bullfrog micro-infusion catheter device, showed local dexamethasone-delivery with Bullfrog yields patient outcomes that compare favorably to that of drug-coated balloons in patients with peripheral artery disease. The company is pursuing more trials of Bullfrog in peripheral artery disease patients even though the device already has a CE mark and 510(k) clearance.

Clinical Trials Research and Development